Autopsy report · NCT03952325

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

“The Sponsor has discontinued the development of tesetaxel”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 294 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Odonate Therapeutics, Inc.

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

Tesetaxel; Tesetaxel; Tesetaxel; Nivolumab; Pembrolizumab; Atezolizumab

Participants

294

Sites

12

Countries

Singapore, South Korea, United States

Trials that died the same way

• A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
  “The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.” (63% match in meaning)
• Magnetic Muscle Stimulation of Abdominal Muscle
  “Sponsor Discontinued due to business decision.” (60% match in meaning)
• Common Safety Follow-up Trial of Tecemotide (L-BLP25)
  “The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.